REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $35.27.

Several equities research analysts recently issued reports on RGNX shares. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. HC Wainwright lowered their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Raymond James restated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $35.00 price objective on shares of REGENXBIO in a report on Wednesday.

Insider Activity

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This represents a 46.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 13.13% of the stock is currently owned by insiders.

Hedge Funds Weigh In On REGENXBIO

Institutional investors have recently modified their holdings of the business. Integral Health Asset Management LLC lifted its stake in REGENXBIO by 25.0% in the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after acquiring an additional 190,000 shares in the last quarter. Quest Partners LLC lifted its position in shares of REGENXBIO by 11,731.0% in the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock worth $491,000 after purchasing an additional 41,645 shares in the last quarter. Squarepoint Ops LLC boosted its holdings in REGENXBIO by 630.9% during the second quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock worth $1,711,000 after purchasing an additional 126,249 shares during the last quarter. Acadian Asset Management LLC acquired a new position in REGENXBIO during the second quarter worth $494,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in REGENXBIO in the third quarter valued at $643,000. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Down 4.7 %

RGNX opened at $9.30 on Thursday. The firm has a market capitalization of $460.72 million, a P/E ratio of -1.85 and a beta of 1.24. REGENXBIO has a 12-month low of $8.44 and a 12-month high of $28.80. The stock has a fifty day moving average of $9.78 and a 200-day moving average of $11.48.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.